Does the media refer more to IONS or AMLX?

In the previous week, Amylyx Pharmaceuticals had 24 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 18 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CYTK or AMLX?

In the previous week, Amylyx Pharmaceuticals had 34 more articles in the media than Cytokinetics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 8 mentions for Cytokinetics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Cytokinetics' score of 0.65 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or AMLX more profitable?

Spyre Therapeutics' return on equity of -30.74% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media favor SYRE or AMLX?

In the previous week, Amylyx Pharmaceuticals had 37 more articles in the media than Spyre Therapeutics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 5 mentions for Spyre Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Spyre Therapeutics' score of 0.43 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is AMLX or PCVX more profitable?

Vaxcyte's return on equity of -37.56% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -52.92% -48.53% Vaxcyte N/A -37.56% -33.62%

Does the media refer more to AMLX or PCVX?

In the previous week, Amylyx Pharmaceuticals had 38 more articles in the media than Vaxcyte. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.07 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AMLX or IMVT more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -52.92% -48.53% Immunovant N/A -69.59% -62.49%

Does the media refer more to AMLX or IMVT?

In the previous week, Amylyx Pharmaceuticals had 34 more articles in the media than Immunovant. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.97 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Amylyx Pharmaceuticals (AMLX) Competitors

$38.66 -1.00 (-2.52%)

As of 08/21/2026 04:00 PM Eastern

Compare

AMLX vs. IONS, CYTK, SYRE, PCVX, and IMVT

Should you buy Amylyx Pharmaceuticals stock or one of its competitors? Amylyx Pharmaceuticals's main competitors and comparable companies include Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Spyre Therapeutics (SYRE), Vaxcyte (PCVX), and Immunovant (IMVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Amylyx Pharmaceuticals compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Ionis Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals had 24 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 18 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ionis Pharmaceuticals currently has a consensus target price of $94.15, suggesting a potential upside of 57.60%. Amylyx Pharmaceuticals has a consensus target price of $36.25, suggesting a potential downside of 6.23%. Given Ionis Pharmaceuticals' higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Amylyx Pharmaceuticals has lower revenue, but higher earnings than Ionis Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	10.52	-$381.39M	-$3.46	N/A
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Amylyx Pharmaceuticals' return on equity of -52.92% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Summary

Amylyx Pharmaceuticals beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals had 34 more articles in the media than Cytokinetics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 8 mentions for Cytokinetics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Cytokinetics' score of 0.65 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has lower revenue, but higher earnings than Cytokinetics. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	108.60	-$784.96M	-$7.22	N/A
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A

Cytokinetics presently has a consensus target price of $102.20, indicating a potential upside of 33.00%. Amylyx Pharmaceuticals has a consensus target price of $36.25, indicating a potential downside of 6.23%. Given Cytokinetics' higher possible upside, equities analysts clearly believe Cytokinetics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Cytokinetics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Summary

Amylyx Pharmaceuticals beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Spyre Therapeutics presently has a consensus target price of $111.69, indicating a potential upside of 4.89%. Amylyx Pharmaceuticals has a consensus target price of $36.25, indicating a potential downside of 6.23%. Given Spyre Therapeutics' higher probable upside, equities analysts plainly believe Spyre Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Spyre Therapeutics' return on equity of -30.74% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Spyre Therapeutics has a beta of 3.03, suggesting that its stock price is 203% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals had 37 more articles in the media than Spyre Therapeutics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 5 mentions for Spyre Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Spyre Therapeutics' score of 0.43 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	10,522.17	-$155.20M	-$1.95	N/A
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A

Summary

Amylyx Pharmaceuticals beats Spyre Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Vaxcyte (NASDAQ:PCVX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Vaxcyte's return on equity of -37.56% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Vaxcyte	N/A	-37.56%	-33.62%

Amylyx Pharmaceuticals has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amylyx Pharmaceuticals currently has a consensus price target of $36.25, indicating a potential downside of 6.23%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 37.34%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Amylyx Pharmaceuticals has higher revenue and earnings than Vaxcyte. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A

In the previous week, Amylyx Pharmaceuticals had 38 more articles in the media than Vaxcyte. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.07 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amylyx Pharmaceuticals beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Immunovant?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Immunovant (NASDAQ:IMVT) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Amylyx Pharmaceuticals currently has a consensus price target of $36.25, suggesting a potential downside of 6.23%. Immunovant has a consensus price target of $44.00, suggesting a potential downside of 0.83%. Given Immunovant's higher probable upside, analysts plainly believe Immunovant is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Amylyx Pharmaceuticals has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals had 34 more articles in the media than Immunovant. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.97 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has higher revenue and earnings than Immunovant. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Amylyx Pharmaceuticals' return on equity of -52.92% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Immunovant	N/A	-69.59%	-62.49%

Summary

Amylyx Pharmaceuticals beats Immunovant on 11 of the 15 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMLX vs. The Competition

Export

Metric	Amylyx Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.31B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-27.03	11.62	272.60	24.24
Price / Sales	49.30	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	17.98	16.80	13.05	6.20
Net Income	-$144.74M	-$12.50M	$3.47B	$348.59M
7 Day Performance	78.73%	3.29%	2.09%	0.08%
1 Month Performance	119.78%	8.23%	6.64%	3.88%
1 Year Performance	315.70%	55.05%	25.02%	16.98%

Amylyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMLX Amylyx Pharmaceuticals	1.7938 of 5 stars	$38.66 -2.5%	$36.25 -6.2%	+315.7%	$4.31B	$87.37M	N/A	200	Trending News Analyst Forecast Analyst Revision
IONS Ionis Pharmaceuticals	3.5688 of 5 stars	$58.63 +2.4%	$94.65 +61.4%	+39.9%	$9.51B	$944M	N/A	1,402	News Coverage Positive News Analyst Upgrade Options Volume
CYTK Cytokinetics	3.3677 of 5 stars	$75.87 +2.3%	$102.20 +34.7%	+100.4%	$9.22B	$88.04M	N/A	250	Insider Trade
SYRE Spyre Therapeutics	1.4993 of 5 stars	$104.60 +0.9%	$111.69 +6.8%	+512.7%	$9.11B	$890K	N/A	73
PCVX Vaxcyte	1.9709 of 5 stars	$60.22 +3.7%	$86.00 +42.8%	+93.9%	$8.64B	N/A	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMLX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. IONS, CYTK, SYRE, PCVX, and IMVT

How does Amylyx Pharmaceuticals compare to Ionis Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Cytokinetics?

Summary

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Summary

How does Amylyx Pharmaceuticals compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. IONS, CYTK, SYRE, PCVX, and IMVT

How does Amylyx Pharmaceuticals compare to Ionis Pharmaceuticals?

Which has more volatility and risk, IONS or AMLX?

Does the media refer more to IONS or AMLX?

Do institutionals & insiders hold more shares of IONS or AMLX?

Do analysts prefer IONS or AMLX?

Which has stronger earnings & valuation, IONS or AMLX?

Is IONS or AMLX more profitable?

Summary

How does Amylyx Pharmaceuticals compare to Cytokinetics?

Do insiders & institutionals believe in CYTK or AMLX?

Does the media favor CYTK or AMLX?

Which has preferable earnings and valuation, CYTK or AMLX?

Do analysts recommend CYTK or AMLX?

Which has more volatility & risk, CYTK or AMLX?

Is CYTK or AMLX more profitable?

Summary

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Do institutionals & insiders have more ownership in SYRE or AMLX?

Do analysts rate SYRE or AMLX?

Is SYRE or AMLX more profitable?

Which has more volatility & risk, SYRE or AMLX?

Does the media favor SYRE or AMLX?

Which has stronger valuation and earnings, SYRE or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Is AMLX or PCVX more profitable?

Which has more volatility & risk, AMLX or PCVX?

Do institutionals & insiders believe in AMLX or PCVX?

Do analysts recommend AMLX or PCVX?

Which has higher valuation and earnings, AMLX or PCVX?

Does the media refer more to AMLX or PCVX?

Summary

How does Amylyx Pharmaceuticals compare to Immunovant?

Do institutionals & insiders hold more shares of AMLX or IMVT?

Do analysts prefer AMLX or IMVT?

Which has more risk & volatility, AMLX or IMVT?

Does the media refer more to AMLX or IMVT?

Which has higher earnings & valuation, AMLX or IMVT?

Is AMLX or IMVT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools